Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Closes Collaboration with Biogen Idec After Receiving Second and Third Milestone Payments

NEW YORK, Aug. 13 (GenomeWeb News) - Drug discovery company Syrrx Inc. announced today that it has closed its collaboration with Biogen Idec after receiving the second and third success-based milestone payments from the company.


The company received its first success-based payment from Biogen Idec on  May 27 . According to an agreement signed on Dec. 16, 2003, all success-based payments have now been completed.


Financial terms of the payments were not disclosed.


Syrrx said its collaboration with Biogen Idec allowed the company to apply its expertise in high-throughput protein crystallization to multiple drug targets that Biogen Idec has developed.


Stephen Kaldor, Syrrx's president and chief scientific officer, said that collaboration between the two companies demonstrated that Syrrx can rapidly generate valuable structural data on challenging drug discovery targets.


"We look forward to exploring opportunities to expand our relationship with Biogen Idec in the future," Kaldor said.


The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.